INTEGRATED BIOPHARMA INC Quarterly Deferred Federal Income Tax Expense (Benefit) in USD from Q3 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Integrated Biopharma Inc quarterly Deferred Federal Income Tax Expense (Benefit) history and growth rate from Q3 2020 to Q1 2024.
  • Integrated Biopharma Inc Deferred Federal Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $81K, a 800% increase year-over-year.
Deferred Federal Income Tax Expense (Benefit), Quarterly (USD)
Deferred Federal Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $81K +$72K +800% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 -$76K -$72K -1800% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-12
Q3 2023 $6K +$44K Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q1 2023 $9K +$115K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 -$4K +$440K +99.1% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-12
Q3 2022 -$38K $0 0% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q1 2022 -$106K +$295K +73.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$444K -$696K -276% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-10
Q3 2021 -$38K -$311K -114% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q1 2021 -$401K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $252K Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-10
Q3 2020 $273K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.